{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T07:14:04Z","timestamp":1788160444195,"version":"build-2803163510"},"reference-count":48,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T00:00:00Z","timestamp":1787961600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Value & Access Think Tank"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr. Oncol.","Current Oncology"],"abstract":"<jats:p>Background: Timely public reimbursement of innovative medicines remains a challenge in Canada despite expedited regulatory review pathways. This study evaluated whether an accelerated reimbursement pathway, similar to Ontario\u2019s Funding Accelerated for Specific Treatments (FAST) for oncology drugs approved through Project Orbis could improve access for therapies approved through Health Canada\u2019s Priority Review (PR) pathway, extending to indications beyond oncology. Methods: Health Canada drug submissions completed between 2021 and 2025 were reviewed to characterize PR, Notice of Compliance with conditions (NOC\/c), and Project Orbis. Drug submissions completed in 2022 were selected for detailed analysis. Drug review and approval process data were compiled from Health Canada (HC), Canada\u2019s Drug Agency (CDA-AMC), the pan-Canadian Pharmaceutical Alliance (pCPA), Ontario government, and manufacturer sources. Time from Health Canada Notice of Compliance (NOC) to Ontario public listing was compared for Orbis, PR non-Orbis, and FAST therapies. Results: Among drugs approved in 2022, mean time from NOC to Ontario listing was 625.29 \u00b1 365.80 days for PR non-Orbis and 604.18 \u00b1 283.92 days for Orbis. FAST therapies were listed in 229.22 \u00b1 140.50 days, approximately 60% faster than Orbis and PR non-Orbis. Half of PR approvals in 2022 were not associated with Project Orbis and were therefore ineligible for existing accelerated reimbursement pathways. Conclusions: The Ontario FAST program is associated with substantially shorter times to public listing for novel oncology medicines. Extending a similar accelerated access pathway to therapies approved through PR could improve timely and equitable patient access in Canada.<\/jats:p>","DOI":"10.3390\/curroncol33090517","type":"journal-article","created":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T05:55:56Z","timestamp":1788155756000},"page":"517","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Assessing the Opportunity for an Accelerated Access Pathway for Health Canada Priority Review Drugs: A Comparative Analysis with Ontario\u2019s FAST Pilot Program"],"prefix":"10.3390","volume":"33","author":[{"given":"Catherine Y.","family":"Lau","sequence":"first","affiliation":[{"name":"Independent Researcher, 158 Front Street E, Toronto, ON M5A 0K9, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9165-5342","authenticated-orcid":false,"given":"Arif","family":"Mitha","sequence":"additional","affiliation":[{"name":"20Sense Corp., Toronto, ON M4J 1G2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"Wills","sequence":"additional","affiliation":[{"name":"20Sense Corp., Toronto, ON M4J 1G2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,29]]},"reference":[{"key":"ref_1","unstructured":"Innovative Medicines Canada (2026, May 18). Public Reimbursement Delay for New Medicines. Available online: https:\/\/innovativemedicines.ca\/wp-content\/uploads\/2020\/07\/CADTH-TTL-8.5x11-EN-Final.pdf."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.3390\/curroncol31040136","article-title":"Access to Oncology Medicines in Canada: Consensus Forum for Recommendations for Improvement","volume":"31","author":"Sehdev","year":"2024","journal-title":"Curr. Oncol."},{"key":"ref_3","unstructured":"Grant, K., and The Globe and Mail (2026, June 29). The Slow-Release Dose. Available online: https:\/\/www.theglobeandmail.com\/canada\/article-canadians-can-wait-years-to-get-drugs-regulators-have-already-deemed\/."},{"key":"ref_4","unstructured":"US Food and Drug Administration (2026, April 28). Priority Review, Available online: https:\/\/www.fda.gov\/patients\/fast-track-breakthrough-therapy-accelerated-approval-priority-review\/priority-review."},{"key":"ref_5","unstructured":"European Medicines Agency (2026, April 28). PRIME: Priority Medicines. Available online: https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/research-development\/prime-priority-medicines."},{"key":"ref_6","unstructured":"Health Canada (2026, April 28). Guidance for Industry\u2014Priority Review of Drug Submissions. Available online: https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-health-products\/drug-products\/applications-submissions\/guidance-documents\/priority-review\/drug-submissions.html."},{"key":"ref_7","unstructured":"Adjutor Group (2026, April 28). Australia\u2019s TGA Priority Review Pathway. Available online: https:\/\/www.adjutor.com.au\/australias-tga-priority-review-pathway."},{"key":"ref_8","unstructured":"Health Canada (2026, April 28). Drug and Health Product Submissions Under Review (SUR): Overview. Available online: https:\/\/www.canada.ca\/en\/health-canada\/services\/drug-health-product-review-approval\/submissions-under-review.html."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"100635","DOI":"10.1016\/j.jcpo.2025.100635","article-title":"Therapeutic Value of Oncology Drugs Approved by Health Canada through Project Orbis: A Cross-Sectional Study","volume":"46","author":"Lexchin","year":"2025","journal-title":"J. Cancer Policy"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e006816","DOI":"10.1136\/bmjopen-2014-006816","article-title":"Health Canada\u2019s Use of Its Priority Review Process for New Drugs: A Cohort Study","volume":"5","author":"Lexchin","year":"2015","journal-title":"BMJ Open"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e023605","DOI":"10.1136\/bmjopen-2018-023605","article-title":"Health Canada\u2019s Use of Expedited Review Pathways and Therapeutic Innovation, 1995\u20132016: Cross-Sectional Analysis","volume":"8","author":"Lexchin","year":"2018","journal-title":"BMJ Open"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"5599","DOI":"10.3390\/curroncol31090414","article-title":"Is Canada Moving towards a More Agile Regulatory Approval and Reimbursement Process with a Shifting Role for Real-World Evidence (RWE) for Oncology Drugs?","volume":"31","author":"Lau","year":"2024","journal-title":"Curr. Oncol."},{"key":"ref_13","unstructured":"Health Canada (2026, April 28). Notice of Compliance with conditions (NOC\/c). Available online: https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-health-products\/drug-products\/notice-compliance\/conditions.html."},{"key":"ref_14","unstructured":"Canada\u2019s Drug Agency\u2014L\u2019Agence des Medicaments du Canada (2026, August 22). The Drug System in Canada: By the Numbers. Available online: https:\/\/www.cda-amc.ca\/data-systems-and-analytics-summary-0."},{"key":"ref_15","unstructured":"Canada\u2019s Drug Agency\u2014L\u2019Agence des Medicaments du Canada (2026, June 20). Our Time-Limited Recommendation Category Aims to Support Earlier Access to Promising Drugs. Available online: https:\/\/www.cda-amc.ca\/news\/our-time-limited-recommendation-category-aims-support-earlier-access-promising-drugs."},{"key":"ref_16","unstructured":"Pan-Canadian Pharmaceutical Alliance (2026, June 20). Temporary Access Process. Available online: https:\/\/pcpa-app.ca\/negotiations\/processes-and-frameworks\/temporary-access-process."},{"key":"ref_17","unstructured":"Canada\u2019s Drug Agency\u2014L\u2019Agence des Medicaments du Canada (2026, June 20). New Analysis Examines Role of Conditional Approvals on Access to Promising Oncology Therapies. Available online: https:\/\/www.cda-amc.ca\/news\/new-analysis-examines-role-conditional-approvals-access-promising-oncology-therapies."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Wills, A. (2024). Expanding the Eligibility Criteria for Drugs in Canada\u2019s Time-Limited Health Technology Assessment and Temporary Drug Access Processes Will Further Accelerate Access to New Medicines. J. Pharm. Pharm. Sci., 27.","DOI":"10.3389\/jpps.2024.13694"},{"key":"ref_19","unstructured":"Canada\u2019s Drug Agency\u2014L\u2019Agence des Medicaments du Canada (2026, June 20). Lurbinectedin. Available online: https:\/\/www.cda-amc.ca\/lurbinectedin-0."},{"key":"ref_20","unstructured":"US Food and Drug Administration (2026, April 28). Project Orbis, a Framework for Concurrent Submission and Review of Oncology Products, Available online: https:\/\/www.fda.gov\/about-fda\/oncology-center-excellence\/project-orbis."},{"key":"ref_21","unstructured":"Health Canada (2026, April 28). Project Orbis. Available online: https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-health-products\/international-activities\/project-orbis.html."},{"key":"ref_22","unstructured":"Australian Government, and Therapeutic Goods Administration (2026, April 28). Project Orbis: Project Orbis Provides a Framework for the Collaborative Review of Promising New Cancer Treatments Among International Regulatory Partners, Available online: https:\/\/www.tga.gov.au\/about-us\/international-engagements\/project-orbis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/S1470-2045(24)00286-9","article-title":"Clinical Benefit, Reimbursement Outcomes, and Prices of FDA-Approved Cancer Drugs Reviewed through Project Orbis in the USA, Canada, England, and Scotland: A Retrospective, Comparative Analysis","volume":"25","author":"Jenei","year":"2024","journal-title":"Lancet Oncol."},{"key":"ref_24","unstructured":"Government of Ontario (2026, April 28). Funding Accelerated for Specific Treatments (FAST) Pilot Program, Available online: https:\/\/www.ontario.ca\/page\/funding-accelerated-specific-treatments-fast-pilot-program."},{"key":"ref_25","unstructured":"Hannay, C., Grant, K., and The Globe and Mail (2026, August 22). Ontario to Offer Early Access to Some New Cancer Drugs in Pilot Project. Available online: https:\/\/www.theglobeandmail.com\/canada\/article-ontario-cancer-drug-pilot-project-prices\/."},{"key":"ref_26","unstructured":"Dunn, L., and Morse Consulting (2026, June 20). Ontario\u2019s FAST Pilot: Early Data Shows over 60% Faster Time to Listing. Available online: https:\/\/morseconsulting.ca\/insights\/ontario-fast-early-results\/?utm_source=linkedin&utm_medium=social&utm_campaign=tl-fast-jun-2026."},{"key":"ref_27","unstructured":"Pan-Canadian Pharmaceutical Alliance (2026, April 28). Early Negotiation Process (ENP). Available online: https:\/\/www.pcpacanada.ca\/enp-pathway."},{"key":"ref_28","unstructured":"Colorectal Cancer Resource, and Action Network (2026, June 29). Patient Organizations Welcome Approval of Six Life-Extending Cancer Treatments Through Ontario\u2019s FAST Program, Urge National Expansion. Available online: https:\/\/www.newswire.ca\/news-releases\/patient-organizations-welcome-approval-of-six-life-extending-cancer-treatments-through-ontario-s-fast-program-urge-national-expansion-871944929.html."},{"key":"ref_29","unstructured":"Innovative Medicines Canada (2026, June 29). IMC Applauds Ontario Government\u2019s Launch of New FAST Program to Accelerate Patient Access to Innovative Medicines. Available online: https:\/\/innovativemedicines.ca\/newsroom\/all-news\/imc-applauds-ontario-governments-launch-of-new-fast-program-to-accelerate-patient-access-to-innovative-medicines\/."},{"key":"ref_30","unstructured":"Government of Ontario (2026, May 03). Exceptional Access Program Product Prices, Available online: https:\/\/www.ontario.ca\/page\/exceptional-access-program-product-prices."},{"key":"ref_31","unstructured":"Government of Ontario (2026, June 20). Ontario Expanding Access to Lifechanging Treatment for Cystic Fibrosis, Available online: https:\/\/news.ontario.ca\/en\/release\/1002182\/ontario-expanding-access-to-lifechanging-treatment-for-cystic-fibrosis."},{"key":"ref_32","unstructured":"Government of Ontario (2026, June 20). Ontario First in Canada to Administer New Publicly Funded Prostate Cancer Care Treatment, Available online: https:\/\/news.ontario.ca\/en\/release\/1005576\/ontario-first-in-canada-to-administer-new-publicly-funded-prostate-cancer-care-treatment."},{"key":"ref_33","unstructured":"Melanoma Canada (2026, June 20). Kimmtrak (Tebentafusp). Available online: https:\/\/melanomacanada.ca\/diagnosis-and-treatment\/rare-melanomas\/kimmtrak-tebentafusp\/."},{"key":"ref_34","unstructured":"Cancer Care Ontario (2026, June 20). Pembrolizumab\u2014Adjuvant Treatment for Renal Cell Carcinoma. Available online: https:\/\/www.cancercareontario.ca\/en\/system\/files_force\/drugeligibility\/Pembrolizumab%20-%20Adjuvant%20Treatment%20for%20Renal%20Cell%20Carcinoma_0.pdf?download=1."},{"key":"ref_35","unstructured":"Cancer Care Ontario (2026, June 20). Pembrolizumab\u2014Locally Recurrent Unresectable or Metastatic Triple Negative Breast Cancer. Available online: https:\/\/www.cancercareontario.ca\/en\/system\/files_force\/drugeligibility\/Pembrolizumab%20-%20Locally%20Recurrent%20Unresectable%20or%20Metastatic%20Triple%20Negative%20Breast%20Cancer_0.pdf?download=1."},{"key":"ref_36","unstructured":"Cancer Care Ontario (2026, June 20). Pembrolizumab (Adult and Pediatric)\u2014Adjuvant Treatment for Completely Resected Stage IIB or IIC Melanoma. Available online: https:\/\/www.cancercareontario.ca\/en\/system\/files_force\/drugeligibility\/Pembrolizumab%20%28Adult%20and%20Pediatric%29%20-%20Adjuvant%20Treatment%20for%20Completely%20Resected%20Stage%20IIB%20or%20IIC%20Melanoma.pdf?download=1."},{"key":"ref_37","unstructured":"Bristol-Myers Squibb Canada (2026, June 20). OPDIVO\u00ae Plus YERVOY\u00ae Reimbursed Under Ontario\u2019s FAST Program as First-Line Treatment for Advanced Liver Cancer. Available online: https:\/\/www.newswire.ca\/news-releases\/opdivo-r-plus-yervoy-r-reimbursed-under-ontario-s-fast-program-as-first-line-treatment-for-advanced-liver-cancer-811686180.html."},{"key":"ref_38","unstructured":"Servier Canada (2026, June 20). Ontario Becomes the First Province to Publicly Reimburse the First Targeted Oral Therapy for Adults with Grade 2 IDH-Mutant Glioma. Available online: https:\/\/www.newswire.ca\/news-releases\/ontario-becomes-the-first-province-to-publicly-reimburse-the-first-targeted-oral-therapy-for-adults-with-grade-2-idh-mutant-glioma--842363324.html."},{"key":"ref_39","unstructured":"Hoffmann-LaRoche Limited (Roche Canada) (2026, June 20). Itovebi\u00ae (Inavolisib) Marks Milestone as the First Breast Cancer Treatment Funded Through Ontario\u2019s New Faster Access Program. Available online: https:\/\/www.newswire.ca\/news-releases\/itovebi-r-inavolisib-marks-milestone-as-the-first-breast-cancer-treatment-funded-through-ontario-s-new-faster-access-program-827694141.html."},{"key":"ref_40","unstructured":"Pfizer (2026, June 20). Pfizer\u2019s BRAFTOVI\u00ae Becomes First Pfizer Therapy to Receive Priority Access Under Ontario\u2019s FAST Program, Accelerating Treatment for Canadians with Metastatic Colorectal Cancer. Available online: https:\/\/www.pfizer.ca\/en\/media-centre\/pfizers-braftovi-becomes-first-pfizer-therapy-to-receive-priority-access-under-ontarios-fast-program-accelerating-treatment-for-canadians-with-metastatic-colorectal-cancer."},{"key":"ref_41","unstructured":"Ontario Ministry of Health\u2019s Drug Programs Delivery (HPDD) Personal communication."},{"key":"ref_42","unstructured":"20Sense (2026, June 20). From Approval to Access: The Experts Weigh in. Available online: https:\/\/www.20sense.ca\/articles\/33-03."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"20542704231166620","DOI":"10.1177\/20542704231166620","article-title":"Prediction of Therapeutic Value of New Drugs Approved by Health Canada from 2011\u22122020: A Cross-Sectional Study","volume":"14","author":"Lexchin","year":"2023","journal-title":"JRSM Open"},{"key":"ref_44","unstructured":"Rawson, N.S.B., and Adams, J. (2026, June 20). Rare Disease Sufferers in Canada\u2014Orphans of \u201cUniversal\u201d Medicare: Nigel S.B. Rawson and John Adams. Available online: https:\/\/macdonaldlaurier.ca\/rare-disease-sufferers-in-canada-orphans-of-universal-medicare-nigel-s-b-rawson-and-john-adams."},{"key":"ref_45","unstructured":"Health Canada (2026, June 18). Drugs for Rare Diseases Bilateral Agreements: Common List of Drugs. Available online: https:\/\/www.canada.ca\/en\/health-canada\/corporate\/transparency\/health-agreements\/shared-health-priorities\/drugs-for-rare-diseases-bilateral-agreements\/common-list-drugs.html."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"8916","DOI":"10.34172\/ijhpm.8916","article-title":"Orphan Drug Approval in Canada, 1999\u20132022: A Cross-Sectional Study","volume":"14","author":"Lexchin","year":"2025","journal-title":"Int. J. Health Policy Manag."},{"key":"ref_47","unstructured":"C.D. Howe Institute (2026, June 20). Ottawa Can Make Canada Work Better by Using its Constitutional Authority to Raze Internal Trade Barriers. Available online: https:\/\/cdhowe.org\/publication\/ottawa-can-make-canada-work-better-by-using-its-constitutional-authority-to-raze-internal-trade-barriers\/."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"975","DOI":"10.2147\/CEOR.S567932","article-title":"Consequences of Canada\u2019s Drug Agency Reimbursement Recommendations for New Medicines and Pan-Canadian Pharmaceutical Alliance Price Negotiations on Patient Access","volume":"17","author":"Rawson","year":"2025","journal-title":"Clin. Outcomes Res."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/9\/517\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T06:21:27Z","timestamp":1788157287000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/9\/517"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,29]]},"references-count":48,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["curroncol33090517"],"URL":"https:\/\/doi.org\/10.3390\/curroncol33090517","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,29]]}}}